Ngā hua rapu - Chang, Ching-Fu

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC mā Wu, Chiao-En, Chang, Ching-Fu, Kou-Sheng, Liao, Chiang, Ju, Lee, Shih-Wei, Chiu, Yu-Chi

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study mā Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma mā Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model mā Chang, Ching-Fu, Huang, Pei-Wei, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Hung, Yu-Shin, Chou, Wen-Chi

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI mā Chang, John Wen-Cheng, Huang, Chen-Yang, Fang, Yueh-Fu, Chang, Ching-Fu, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Wu, Chiao-En

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients mā Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, Wu, Chiao‐En

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy mā Lin, Chia-Hsin, Hung, Tsung-Min, Chang, Yu-Chuan, Hsieh, Chia-Hsun, Shih, Ming-Chieh, Huang, Shih-Ming, Yang, Chan-Keng, Chang, Ching-Fu, Chan, Sheng-Chieh, Yap, Wing-Keen

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy mā Huang, Pei‐Wei, Chang, Ching‐Fu, Hung, Chia‐Yen, Hsueh, Shun‐Wen, Chang, Pei‐Hung, Yeh, Kun‐Yun, Chen, Jen‐Shi, Chen, Yen‐Yang, Lu, Chang‐Hsien, Hung, Yu‐Shin, Chou, Wen‐Chi

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies mā Wu, Chiao-En, Yang, Chan-Keng, Peng, Meng-Ting, Huang, Pei-Wei, Chang, Ching-Fu, Yeh, Kun-Yun, Chen, Chun-Bing, Wang, Chih-Liang, Hsu, Chao-Wei, Chen, I-Wen, Lin, Cheng-Tao, Ueng, Shir-Hwa, Lin, Gigin, Lin, Yu-Fen, Cheng, Chi-Yuan, Chang, John Wen-Cheng

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa